Carbapenem-Based Antibiotics Global Market Report 2024

Description

Carbapenem-based antibiotics represent a class of broad-spectrum antibacterial drugs known for their high efficacy against various bacterial infections. These antibiotics are particularly effective against both gram-positive and gram-negative bacteria, including strains that may be resistant to other types of antibiotics.

The primary types of carbapenem-based antibiotics include meropenem, imipenem, doripenem, tebipenem, and others. Meropenem, for instance, is a broad-spectrum antibiotic that works by inhibiting bacterial cell wall synthesis, making it effective against a wide range of bacterial infections. It is employed in the treatment of serious bacterial infections such as pneumonia, meningitis, intra-abdominal infections, urinary tract infections, and skin and soft tissue infections. Carbapenem-based antibiotics find application in treating various conditions, including intra-abdominal infections, urinary tract infections, pneumonia, bacterial meningitis, skin and skin structure infections, acute pelvic infections, prophylaxis of surgical site infection, respiratory tract infections, and gynecologic infections. These antibiotics are available through different distribution channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

The carbapenem-based antibiotics market research report is one of a series of new reports from The Business Research Company that provides carbapenem-based antibiotics market statistics, including the carbapenem-based antibiotics industry's global market size, regional shares, competitors with a carbapenem-based antibiotics market share, detailed carbapenem-based antibiotics market segments, market trends, and opportunities, and any further data you may need to thrive in the carbapenem-based antibiotics industry. This carbapenem-based antibiotics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The carbapenem-based antibiotics market size has grown strongly in recent years. It will grow from $4.43 billion in 2023 to $4.66 billion in 2024 at a compound annual growth rate (CAGR) of 5.1%. The growth observed in the historic period can be attributed to factors such as the occurrence of epidemics and pandemics, an increase in chronic diseases, expansion of healthcare infrastructure, rapid urbanization, and the impact of natural disasters and health emergencies.

The carbapenem-based antibiotics market size is expected to see strong growth in the next few years. It will grow to $5.71 billion in 2028 at a compound annual growth rate (CAGR) of 5.2%. The anticipated growth in the forecast period is driven by factors such as the increased incidence of hospital-acquired infections, the emergence of multi-drug resistant strains, a growing aging population, a rise in surgical procedures, the proliferation of infectious diseases, and changing demographics. Major trends expected in the forecast period include a focus on supply chain resilience and security, the development of alternative treatment options, a shift towards outpatient settings, a growing awareness of antimicrobial stewardship, and the adoption of precision medicine approaches.

The projected rise in carbapenem-based antibiotics market growth is attributed to the escalating incidence of bacterial infections. These infections, caused by microscopic organisms known as bacteria, lead to various diseases and symptoms. Carbapenem-based antibiotics are specifically designed to address severe or multidrug-resistant bacterial infections, encompassing both gram-positive and gram-negative bacteria. For instance, as reported by the UK Health Security Agency (UKHSA) in November 2022, there was a 2.2% increase in anticipated total antibiotic-resistant severe infections in 2021. Hence, the surge in bacterial infections is a key driver propelling the growth of the carbapenem-based antibiotics market.

The expansion of the carbapenem-based antibiotics market is anticipated due to the rising number of surgical procedures performed. Surgical procedures encompass a range of medical interventions carried out by qualified surgeons to address diseases, injuries, or conditions affecting different body parts. Carbapenems exhibit a wide spectrum of activity, effectively combating infections within the abdominal cavity, reducing the necessity for combination therapy, simplifying treatment protocols for surgical patients, and proving efficacious in meningitis treatment. For instance, data from the American Society for Metabolic and Bariatric Surgery (ASMBS) in June 2022 revealed that approximately 262,893 bariatric surgeries were conducted in 2021. Therefore, the escalation in surgical procedures directly contributes to the growth of the carbapenem-based antibiotics market.

The prevailing trend driving the carbapenem-based antibiotics market is the emphasis on product innovations. Major industry players within this market segment are actively engaged in innovating their product lines as a strategic approach to maintain their market positions. For example, in September 2021, BDR Pharmaceuticals International Pvt. Ltd., an India-based pharmaceutical company, introduced biapenem into the market. Biapenem is specifically designed for individuals afflicted with lower respiratory infections, complex urinary tract infections, or intra-abdominal infections. Clinical studies have showcased that Biapenem exhibits both clinical and bacteriological efficacy comparable to imipenem/cilastatin in treating patients affected by these ailments.

Leading companies operating in the carbapenem-based antibiotics market are directing their focus towards investments to augment their market revenues. A case in point is Pfizer Inc., a US-based pharmaceutical and biotechnology corporation, which, in June 2021, allocated $40 million in investment toward Spero Therapeutics Inc. This investment granted Pfizer the rights to develop, produce, and market SPR206 outside of the United States and Asia. This financial arrangement is expected to bolster the ongoing clinical advancement of SPR720 and SPR206, providing Spero with substantial financial flexibility and capital. Pfizer's investment aligns with its strategic objective of fostering pioneering research and meeting patient needs, while concurrently empowering Spero to advance clinical development and expand global access to their products. Spero Therapeutics Inc., a US-based biopharmaceutical company dedicated to creating novel therapies for bacterial infections, stands to benefit significantly from this collaboration.

In September 2022, GSK PLC, a pharmaceutical and biotechnology company based in the UK, and Spero Therapeutics, Inc. entered into an exclusive license agreement. The agreement involved an upfront payment of $66 million, with the potential for future milestone payments and tiered royalties. This exclusive license granted GSK the commercialization rights for tebipenem HBr in all regions except for Japan and certain other Asian countries. Spero Therapeutics, a US-based clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments and medicines for bacterial infections, including multi-drug resistant and rare diseases, particularly in the realm of carbapenem oral antibiotics.

Major companies operating in the carbapenem-based antibiotics market report are Pfizer Inc., Merck & Co. Inc., Saint-Gobain S.A., Fresenius Kabi LLC, GlaxoSmithKline PLC, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., AstraZeneca PLC, Meiji Holdings Co. Ltd., Sandoz International GmbH, Sumitomo Dainippon Pharma Co. Ltd., Shionogi & Co Ltd., Aurobindo Pharma Ltd., Acurx Pharmaceuticals LLC, Daewoong Pharmaceutical Co. Ltd., CeramTec GmbH, ACS Dobfar S.p.A, JW Pharmaceutical Corp, Centrient Pharmaceuticals Co, Spero Therapeutics Inc., Kopran Limited, Savior Lifetec Corporation, Amedica Corporation, Flagship Biotech International Pvt. Ltd., Iterum Therapeutics PLC, Cam Carbapenem-based antibiotics BV, Intelicure Lifesciences, Ikeda Corporation

North America was the largest region in the Carbapenem-Based Antibiotics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the carbapenem-based antibiotics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the carbapenem-based antibiotics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The carbapenem-based antibiotics market consists of sales of imipenem-cilastatin, meropenem, ertapenem, doripenem, biapenem, panipenem, tebipenem, razupenem, tomopenem, and faropenem. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Carbapenem-Based Antibiotics Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on carbapenem-based antibiotics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for carbapenem-based antibiotics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The carbapenem-based antibiotics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

1) By Type: Meropenem; Imipenem; Doripenem; Tebipenem; Other Types
2) By Indication: Intra-abdominal Infections; Urinary Tract Infections; Pneumonia; Bacterial Meningitis; Skin and Skin Structure Infections; Acute Pelvic Infections; Prophylaxis of Surgical Site Infection; Respiratory Tract Infections; Gynecological Infections; Other Indications
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; Saint-Gobain S.A.; Fresenius Kabi LLC; GlaxoSmithKline Plc
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r13581

1. Executive Summary

2. Carbapenem-Based Antibiotics Market Characteristics

3. Carbapenem-Based Antibiotics Market Trends And Strategies

4. Carbapenem-Based Antibiotics Market - Macro Economic Scenario

4.1. Impact Of High Inflation On The Market
4.2. Ukraine-Russia War Impact On The Market
4.3. COVID-19 Impact On The Market

5. Global Carbapenem-Based Antibiotics Market Size and Growth

5.1. Global Carbapenem-Based Antibiotics Market Drivers and Restraints
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints Of The Market
5.2. Global Carbapenem-Based Antibiotics Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global Carbapenem-Based Antibiotics Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Carbapenem-Based Antibiotics Market Segmentation

6.1. Global Carbapenem-Based Antibiotics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Meropenem
Imipenem
Doripenem
Tebipenem
Other Types
6.2. Global Carbapenem-Based Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Intra-abdominal Infections
Urinary Tract Infections
Pneumonia
Bacterial Meningitis
Skin and Skin Structure Infections
Acute Pelvic Infections
Prophylaxis of Surgical Site Infection
Respiratory Tract Infections
Gynecological Infections
Other Indications
6.3. Global Carbapenem-Based Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

7. Carbapenem-Based Antibiotics Market Regional And Country Analysis

7.1. Global Carbapenem-Based Antibiotics Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Carbapenem-Based Antibiotics Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Carbapenem-Based Antibiotics Market

8.1. Asia-Pacific Carbapenem-Based Antibiotics Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Carbapenem-Based Antibiotics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Carbapenem-Based Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Carbapenem-Based Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Carbapenem-Based Antibiotics Market

9.1. China Carbapenem-Based Antibiotics Market Overview
9.2. China Carbapenem-Based Antibiotics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Carbapenem-Based Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Carbapenem-Based Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Carbapenem-Based Antibiotics Market

10.1. India Carbapenem-Based Antibiotics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Carbapenem-Based Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Carbapenem-Based Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Carbapenem-Based Antibiotics Market

11.1. Japan Carbapenem-Based Antibiotics Market Overview
11.2. Japan Carbapenem-Based Antibiotics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Carbapenem-Based Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Carbapenem-Based Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Carbapenem-Based Antibiotics Market

12.1. Australia Carbapenem-Based Antibiotics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Carbapenem-Based Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Carbapenem-Based Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Carbapenem-Based Antibiotics Market

13.1. Indonesia Carbapenem-Based Antibiotics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Carbapenem-Based Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Carbapenem-Based Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Carbapenem-Based Antibiotics Market

14.1. South Korea Carbapenem-Based Antibiotics Market Overview
14.2. South Korea Carbapenem-Based Antibiotics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Carbapenem-Based Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Carbapenem-Based Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Carbapenem-Based Antibiotics Market

15.1. Western Europe Carbapenem-Based Antibiotics Market Overview
15.2. Western Europe Carbapenem-Based Antibiotics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Carbapenem-Based Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Carbapenem-Based Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Carbapenem-Based Antibiotics Market

16.1. UK Carbapenem-Based Antibiotics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Carbapenem-Based Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Carbapenem-Based Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Carbapenem-Based Antibiotics Market

17.1. Germany Carbapenem-Based Antibiotics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Carbapenem-Based Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Carbapenem-Based Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Carbapenem-Based Antibiotics Market

18.1. France Carbapenem-Based Antibiotics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Carbapenem-Based Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Carbapenem-Based Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Carbapenem-Based Antibiotics Market

19.1. Italy Carbapenem-Based Antibiotics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Carbapenem-Based Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Carbapenem-Based Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Carbapenem-Based Antibiotics Market

20.1. Spain Carbapenem-Based Antibiotics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Carbapenem-Based Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Carbapenem-Based Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Carbapenem-Based Antibiotics Market

21.1. Eastern Europe Carbapenem-Based Antibiotics Market Overview
21.2. Eastern Europe Carbapenem-Based Antibiotics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Carbapenem-Based Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Carbapenem-Based Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Carbapenem-Based Antibiotics Market

22.1. Russia Carbapenem-Based Antibiotics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Carbapenem-Based Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Carbapenem-Based Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Carbapenem-Based Antibiotics Market

23.1. North America Carbapenem-Based Antibiotics Market Overview
23.2. North America Carbapenem-Based Antibiotics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Carbapenem-Based Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Carbapenem-Based Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Carbapenem-Based Antibiotics Market

24.1. USA Carbapenem-Based Antibiotics Market Overview
24.2. USA Carbapenem-Based Antibiotics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Carbapenem-Based Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Carbapenem-Based Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Carbapenem-Based Antibiotics Market

25.1. Canada Carbapenem-Based Antibiotics Market Overview
25.2. Canada Carbapenem-Based Antibiotics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Carbapenem-Based Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Carbapenem-Based Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Carbapenem-Based Antibiotics Market

26.1. South America Carbapenem-Based Antibiotics Market Overview
26.2. South America Carbapenem-Based Antibiotics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Carbapenem-Based Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Carbapenem-Based Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Carbapenem-Based Antibiotics Market

27.1. Brazil Carbapenem-Based Antibiotics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Carbapenem-Based Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Carbapenem-Based Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Carbapenem-Based Antibiotics Market

28.1. Middle East Carbapenem-Based Antibiotics Market Overview
28.2. Middle East Carbapenem-Based Antibiotics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Carbapenem-Based Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Carbapenem-Based Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Carbapenem-Based Antibiotics Market

29.1. Africa Carbapenem-Based Antibiotics Market Overview
29.2. Africa Carbapenem-Based Antibiotics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Carbapenem-Based Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Carbapenem-Based Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Carbapenem-Based Antibiotics Market Competitive Landscape And Company Profiles

30.1. Carbapenem-Based Antibiotics Market Competitive Landscape
30.2. Carbapenem-Based Antibiotics Market Company Profiles
- 30.2.1. Pfizer Inc.
  - 30.2.1.1. Overview
  - 30.2.1.2. Products and Services
  - 30.2.1.3. Strategy
  - 30.2.1.4. Financial Performance
- 30.2.2. Merck & Co. Inc.
  - 30.2.2.1. Overview
  - 30.2.2.2. Products and Services
  - 30.2.2.3. Strategy
  - 30.2.2.4. Financial Performance
- 30.2.3. Saint-Gobain S.A.
  - 30.2.3.1. Overview
  - 30.2.3.2. Products and Services
  - 30.2.3.3. Strategy
  - 30.2.3.4. Financial Performance
- 30.2.4. Fresenius Kabi LLC
  - 30.2.4.1. Overview
  - 30.2.4.2. Products and Services
  - 30.2.4.3. Strategy
  - 30.2.4.4. Financial Performance
- 30.2.5. GlaxoSmithKline Plc
  - 30.2.5.1. Overview
  - 30.2.5.2. Products and Services
  - 30.2.5.3. Strategy
  - 30.2.5.4. Financial Performance

31. Carbapenem-Based Antibiotics Market Other Major And Innovative Companies

31.1. Eli Lilly and Company
31.2. Teva Pharmaceutical Industries Ltd.
31.3. AstraZeneca plc
31.4. Meiji Holdings Co. Ltd.
31.5. Sandoz International GmbH
31.6. Sumitomo Dainippon Pharma Co. Ltd.
31.7. Shionogi & Co Ltd.
31.8. Aurobindo Pharma Ltd.
31.9. Acurx Pharmaceuticals, LLC
31.10. Daewoong Pharmaceutical Co. Ltd.
31.11. CeramTec GmbH
31.12. ACS Dobfar S.p.A
31.13. JW Pharmaceutical Corp
31.14. Centrient Pharmaceuticals Co
31.15. Spero Therapeutics Inc.

32. Global Carbapenem-Based Antibiotics Market Competitive Benchmarking

33. Global Carbapenem-Based Antibiotics Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Carbapenem-Based Antibiotics Market

35. Carbapenem-Based Antibiotics Market Future Outlook and Potential Analysis

35.1 Carbapenem-Based Antibiotics Market In 2028 - Countries Offering Most New Opportunities
35.2 Carbapenem-Based Antibiotics Market In 2028 - Segments Offering Most New Opportunities
35.3 Carbapenem-Based Antibiotics Market In 2028 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer